In 2016, the U.S. National Institutes of Health (NIH) announced that it had discovered the first evidence of a new HPV type in the human papillomavirus vaccine, which is marketed under the brand name Gardasil.
This new type of HPV infection, known as a cervical intraepithelial neoplasia (CIN) or HPV-19, has been linked to a lower pelvisespreading rate (LPR) in women, according to researchers at Columbia University Medical Center and the New York City Department of Health and Mental Hygiene.
CIN is characterized by increased cervical secretions, which have been linked in the past to cervical cancer, and cervical inflammation.
The LPR is thought to be related to a reduction in cervical secretion motility and is associated with cervical cancer.
The researchers analyzed data from more than 100,000 women in the New England Journal of Medicine (NEJM) to determine the true prevalence of cervical cancer in women receiving Gardasils.
Their study found that women in this study who received Gardasics had a lower LPR, which translates into a lower risk of cervical injury and cervical cancer among women.
But while the researchers reported the findings, they cautioned that the data were not conclusive and could be misinterpreted.
“Although we have observed that LPR was reduced in Gardasiliine recipients, this finding does not mean that the vaccine caused a reduction of LPR in the general population,” they wrote.
“It is important to note that this study did not compare Gardasill to other HPV vaccines, nor did we have sufficient data to draw any conclusions about the efficacy of Gardasic against cervical cancer.”
More than 30,000 Americans have already been vaccinated with Gardasills so far, and there are currently no known side effects.
As the vaccine has been in widespread use since 2015, the US Department of Defense (DoD) has announced that a second vaccine is planned to be made available in 2021.
It will be the first to be released on a larger scale to the general public, and the first vaccine to be manufactured in the U